Track RXRX in your personal workspace
Monitor performance, SPY relative strength
and WOI View from your watchlist.
Alert me when RXRX price is:
52W Range Position
4%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 16:46 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Weak / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
3.27
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
6
●
Financial Results
HIGH
Recursion Reports First Quarter Financial Results and Provides Business Update
• Multiple milestones achieved or on track across wholly owned and partnered programs • REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable, dose-dependent pharmacokinetics; no DLTs observed to date, supporting ongoing dose escalation • REC-4881...
• Multiple milestones achieved or on track across wholly owned and partnered programs • REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable, dose-dependent pharmacokinetics; no DLTs observed to date, supporting ongoing dose escalation • REC-4881 (FAP / MEK1/2): Strong Phase 2 efficacy signals with FDA engagement initiated to define potential registrational pathway;update expected in 2H26 • REC-4539 (LSD1 inhibitor): First patient dosed in Phase 1; platform-derived, selective, brain-penetrant profile, designed to have a reversible mechanism to reduce on-target platelet toxicity, supporting differentiation in solid tumors and AML • Disciplined capital execution: Reiterate 2026 guidance of <$390 million operational cash burn, supporting runway into early 2028 without additional financing SALT LAKE CITY, May 6, 2026 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates highlighting strong continued pipeline execution, clinical progress and platform advancement, as well as financial results for its first quarter ended March 31, 2026.
8-K Filing•SEC EDGAR
What's Driving RXRX?
📈 Technical recovery is improving
Momentum is Neutral. Watch 3.27 for confirmation and — for structure risk.
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
42.1
◎
How to read this setup
The nearest decision zone is framed by support around 2.84 and resistance near 3.27. A move through resistance would be needed to materially improve the chart, while a break of support would keep the pressure side dominant.